Loading...
•
Mar 31, 2024
Rocket Q1 2024 Earnings Report
Rocket Pharmaceuticals reported financial results for Q1 2024 and highlighted progress in its clinical programs, including the EMA's review of RP-L102 and preparations for the potential approval of KRESLADI.
Key Takeaways
Rocket Pharmaceuticals reported a net loss of $62.1 million for Q1 2024, with cash, cash equivalents, and investments totaling $330.3 million, expected to fund operations into 2026. The company highlighted progress in its clinical programs, including the EMA's review of RP-L102 for Fanconi Anemia and preparations for the potential approval of KRESLADI for severe LAD-I.
EMA accepted the Marketing Authorization Application (MAA) for RP-L102 for the treatment of Fanconi Anemia.
Company remains on track to submit the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in the first half of 2024 for RP-L102.
KRESLADI™ is on track for June 30, 2024, PDUFA date.
Aaron Ondrey was appointed as Chief Financial Officer (CFO).
Forward Guidance
Rocket Pharmaceuticals expects its cash, cash equivalents and investments of $330.3 million as of March 31, 2024, will be sufficient to fund its operations into 2026.
Positive Outlook
- Cash position is expected to fund operations into 2026
- Producing AAV cGMP batches at the Company’s Cranbury, N.J. R&D and manufacturing facility
- Continued development of its six clinical and/or preclinical programs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...